These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 18427122)
1. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Lammerts van Bueren JJ; Bleeker WK; Brännström A; von Euler A; Jansson M; Peipp M; Schneider-Merck T; Valerius T; van de Winkel JG; Parren PW Proc Natl Acad Sci U S A; 2008 Apr; 105(16):6109-14. PubMed ID: 18427122 [TBL] [Abstract][Full Text] [Related]
2. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. Gan HK; Walker F; Burgess AW; Rigopoulos A; Scott AM; Johns TG J Biol Chem; 2007 Feb; 282(5):2840-50. PubMed ID: 17092939 [TBL] [Abstract][Full Text] [Related]
3. A molecular view of anti-ErbB monoclonal antibody therapy. Leahy DJ Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550 [TBL] [Abstract][Full Text] [Related]
4. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559 [TBL] [Abstract][Full Text] [Related]
6. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers. Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. Lu C; Mi LZ; Schürpf T; Walz T; Springer TA J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552 [TBL] [Abstract][Full Text] [Related]
9. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Snyder LC; Astsaturov I; Weiner LM Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752 [TBL] [Abstract][Full Text] [Related]
10. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331 [TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326 [TBL] [Abstract][Full Text] [Related]